| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.6004/JNCCN.2009.0079 |
| P698 | PubMed publication ID | 19755043 |
| P50 | author | Harold J. Burstein | Q109562169 |
| Lori J Pierce | Q100310367 | ||
| P2093 | author name string | Donald A Berry | |
| D Craig Allred | |||
| Allen Gown | |||
| Stuart J Schnitt | |||
| Stephen B Edge | |||
| Antonio C Wolff | |||
| Robert W Carlson | |||
| Lori J Goldstein | |||
| Susan Moench | |||
| M Elizabeth Hammond | |||
| James Dirk Iglehart | |||
| Peter Ravdin | |||
| P4510 | describes a project that uses | immunohistochemistry | Q899285 |
| P921 | main subject | breast cancer | Q128581 |
| immunohistochemistry | Q899285 | ||
| estrogen | Q277954 | ||
| P304 | page(s) | S1-S21; quiz S22-3 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Journal of the National Comprehensive Cancer Network | Q400309 |
| P1476 | title | NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry | |
| P478 | volume | 7 Suppl 6 |
| Q91830300 | A Nomogram To Predict The Overall Survival Of Breast Cancer Patients And Guide The Postoperative Adjuvant Chemotherapy In China |
| Q35925244 | Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. |
| Q37479225 | Analytic variability in immunohistochemistry biomarker studies. |
| Q34709370 | Assessment of DNA methylation status in early stages of breast cancer development |
| Q36676997 | Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione |
| Q64096309 | Clinical potential of mass spectrometry-based proteogenomics |
| Q37128434 | Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q38375829 | Construction and Validation of a Multi-Institutional Tissue Microarray of Invasive Ductal Carcinoma From Racially and Ethnically Diverse Populations |
| Q55399916 | Decreased survival in patients with carcinoma of axillary tail versus upper outer quadrant breast cancers: a SEER population-based study. |
| Q94461787 | Deep learned tissue "fingerprints" classify breast cancers by ER/PR/Her2 status from H&E images |
| Q102075322 | Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains |
| Q26850961 | Developing precision medicine in a global world |
| Q35986087 | Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer |
| Q37788875 | Do Steroid Hormones Play a Role in the Etiology of Glioma? |
| Q38403294 | ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry |
| Q37997046 | Efficacy and pharmacogenomic biomarkers in breast cancer |
| Q34730000 | Emerging understanding of multiscale tumor heterogeneity |
| Q40023474 | Evaluating disparities in inpatient surgical cancer care among American Indian/Alaska Native patients |
| Q51549840 | Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort. |
| Q92840732 | Expression of PGRMC1 in paraffin-embedded tissues of breast cancer |
| Q36236672 | Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy |
| Q38092775 | Hormone receptor expression in breast cancer: postanalytical issues |
| Q36288976 | Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study |
| Q33642280 | ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 |
| Q33736780 | Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies |
| Q84178520 | Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and |
| Q35570005 | Immunohistochemistry and mass spectrometry for highly multiplexed cellular molecular imaging |
| Q89884047 | Immunotherapy for the Treatment of Breast Cancer: Emerging New Data |
| Q36568574 | Indicator measures er/pr and her2 testing among women with invasive breast cancer |
| Q58595085 | Individualized Tumor Therapy: Biomarkers and Possibilities for Targeted Therapy with Natural Products |
| Q35044178 | Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo |
| Q39168537 | Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1? |
| Q39022633 | MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation |
| Q34748331 | Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy |
| Q37120795 | Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines |
| Q42488655 | Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor |
| Q34620545 | Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation |
| Q38012010 | Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer |
| Q35085764 | Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer |
| Q37113312 | Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses |
| Q37350042 | Quantitation of fixative-induced morphologic and antigenic variation in mouse and human breast cancers. |
| Q89690242 | Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer |
| Q26768119 | Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives |
| Q40570290 | The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone |
| Q28075719 | Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation |
| Q37723520 | Which threshold for ER positivity? a retrospective study based on 9639 patients |
Search more.